Raymond James analyst Jayson Bedford raised his price target for Insulet to $135 from $125 and maintained an Outperform rating, saying the company generated significant momentum in the second quarter and the revenue beat was the company's largest in over two years. In a research note to investors, Bedford says it is "tough to poke holes" in Q2, and says the raised guidance implies continued momentum. The analyst notes that Horizon, and possibly Tidepool, launching in late 2020 provides visibility into additional growth drivers, giving him confidence in the sustainability of the underlying growth profile.